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Background: Interferons (IFNs) are a group of cytokines commonly used in the clinical treatment of chronic
hepatitis B (CHB) patients. Their therapeutic effects are highly correlated with recovery of host antiviral immunity.
Clearance of hepatitis B virus (HBV) is mediated partially by activated functional memory T cells. The aims of the
present study were to investigate memory T cell status in patients with different outcomes following pegylated
interferon-α (IFN-α) therapy and to identify new biomarkers for predicting antiviral immune responses.
Methods: Peripheral blood cells were isolated from 23 CHB patients who were treated with pegylated IFN-α at
week 0 (baseline) and week 24. Co-expression of programmed death-1 (PD-1) and CD244 in CD45RO positive T
cells, as well as a subset of CD127 and CXCR4 positive memory T cells were assessed. In addition, perforin,
granzyme B, and interferon-γ (IFN-γ) expressions were also analyzed by flow cytometric analysis after
intracytoplasmic cytokine staining (ICCS). Peripheral blood mononuclear cells (PBMC) isolated at week 24 were
re-challenged with exogenous HBV core antigen, and the percentage of IFN-γ expression, serum HBV DNA loads,
and ALT (alanine aminotransferase) levels were evaluated.
Results: At week 24, PD-1 and CD244 expression in CD8 memory T cells were down-regulated (P < 0.05, P < 0.05,
respectively), along with decreased HBV DNA loads (P < 0.05), while the expressions of partial effector molecules in
CD8 and CD4 memory T cells was up-regulated (P < 0.05,P < 0.05, respectively), especially in the responders. CD127
and CXCR4 were highly expressed in CD8 memory T cells after pegylated IFN-α treatment (P < 0.05), which was
inversely correlated with HBV DNA loads (r = −0.47, P = 0.001). The responders had a higher IFN-γ expression in
memory T cells than the non-responders did after HBV antigen re-stimulation in vitro.
Conclusion: Pegylated IFN-α treatment enhanced recovery of memory T cells in CHB patients by down-regulating
inhibitory receptors and up-regulating effector molecules. The expressions of CXCR4 and CD127 in CD8 memory
T cell may be used as biomarkers for predicting the outcome of treatment.
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Chronic hepatitis B virus infection is the most common
cause of liver cirrhosis and hepatocellular carcinoma in
China [1,2]. The chronicity of HBV infection depends
on viral factors, host immunity, and the intrahepatic
microenvironment. Adaptive immunity plays a vital role
in antiviral effects in the liver and peripheral infections
[3,4]. However, during the progression of chronic HBV
infection, T cell dysfunction is too profound to effect-
ively control viral replication, leading to a decline of viral
clearance. More specifically, exhaustion and depletion of
effector cells hinder T cell homeostasis and antigen-
specific memory T cell formation [5]. During chronic
HBV infection, naive T cells are primed by antigens and
then differentiate into effector T cells. Unless the infec-
tion is cleared following antigen clearance, and the intra-
hepatic inflammation is diminished or substantially
reduced, partially functional effector T cells can further
differentiate into highly polyfunctional memory T cells.
Antigen specific memory T cells keep on self-renewing
and have the potential to proliferate and differentiate
upon encountering antigens again [6,7]. In other words,
memory T cells have recall reaction ability. They are
capable of producing multiple cytokines, such as IFN-γ,
TNF-α, and IL-2, becoming cytolytic, and proliferating
vigorously to become activated functional cells [8].
These cells also have high survival capability and are
maintained for long periods in the absence of antigen.
Pegylated IFN-α is one of the most common thera-
peutic cytokines in the treatment of chronic HBV infec-
tion [9,10]; it relies on host immunity mobilization to
produce antiviral components, such as interleukin-12
and IFN-γ, and to induce the differentiation of adaptive
immunocytes, which block viral protein synthesis and
assemblage of viral structures. Until now, few studies fo-
cused on memory T cell variation and the immunologic
consequences of pegylated IFN-α treatment in chronic
hepatitis B infection [11]. The goal of this study is to in-
vestigate the influence and variation of memory T cell
status after pegylated IFN-α treatment by evaluating the
expression of inhibitory receptors, effector molecules,





HBVDNA loads [log (IU/mL)] 6.85 (4.65-8.06)
ALT(IU/L) 113.6 (42–285)
HBVgenotype (B/C) 6/17
Data are presented as median (range).loads [12], and the capacity to release effector cytokines
by in vitro antigen stimulation [13].
Results
Characteristics of patients
To evaluate the effect of pegylated IFN- α treatment on
memory T cells in CHB infection, 23 CHB patients were
divided into responders (n = 9) and non-responders
(n =14) at week 24. The patients’ characteristics before
treatment are summarized in Table 1. The responders
were patients with normal ALT and HBV DNA loads
that had decreased more than 3log values, and/or e
antigen seroconversion after 24 weeks of the treatment;
the rest of patients were defined as non-responders.
PD-1 and CD244 expressions were down-regulated in
memory T cells
PD-1 and CD244 expressions in CD8 memory T cells
(CD8 + CD45RO+) were simultaneously down-regulated
along with decreased HBV DNA loads after pegylated
IFN-α treatment in all patients (P = 0.018, P = 0.014, re-
spectively), when comparing to baseline expressions
(Figure 1A). In addition, the responders had significant
loss of PD-1 expression in CD8 memory T cells (P = 0.027,
Figure 1B), but CD244 expression in CD8 memory T cells
did not show the same trend (P = 0.57, Figure 1B). Fur-
thermore, the PD-1 expression in CD8 memory T cells
and the HBV DNA loads were moderately correlated in all
patients (r = 0.36, P = 0.02, Figure 1C) whereas CD244 ex-
pression in the same subset of T cells was not correlated
with HBV DNA loads. The expression of PD-1 and
CD244 in CD4 memory T cells had neither significant dif-
ferences nor correlations with DNA loads in all subjects
observed (data not shown).
IFN-γ, perforin and granzyme B expressions were
up-regulated in memory T cells
Upon stimulation with PMA and ionomycin, we tested
the release of IFN-γ by memory T cells. The results
showed that IFN-γ expression on CD4 + CD45RO + T
cells was significantly different between week 0 and week
24 of treatment in both the responders (P = 0.003) andResponders Non-responders
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Figure 1 Percentage of inhibitory receptors expression on CD8
memory T cells in CHB patients. (A) Percentage of PD-1 and
CD244 expression on CD8 memory T cells in all patients at week 0
and week 24. (B) Percentage of PD-1 and CD244 expression on CD8
memory T cells in responder patients at week 0 and week 24. (C)
Correlation between PD-1 expression on CD8 memory T cell and
HBV viral loads.
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IFN-γ expression on CD4 memory T cells after the treat-
ment was higher in the responders than that in the non-
responders (P = 0.047, Figure 2A).
While the expression of IFN-γ on CD8 memory T cells
in the responders is significantly different between week
0 and week 24 of treatment (P = 0.007, Figure 2B), there
was no significant difference in the non-responders be-
tween week 0 and week 24 of treatment, nor was there
any significant difference between the responders and
the non-responders at week 24.
By using gating strategy analysis as shown in Figure 2E,
we found that the expressions of granzyme B (P = 0.04)
and perforin (P = 0.03) on CD8 memory T cells at week 24
in the responders were higher than those at week 0
(Figure 2C) but lower than those in the non-responders
(P = 0.03, P = 0.02, respectively, Figure 2D).
CD127 expression on CD8 memory T cells was
up-regulated
The results from flow cytometric analysis showed that
CD127 expression on CD8 memory T cells was up-
regulated in the responders after 24 weeks of treatment
(P = 0.02, Figure 3A). The percentage of CD8 memory T
cells that expressed CD127 was higher in the responders
than in the non-responders at week 24 (P = 0.03,
Figure 3B). However, there was no difference in the per-
cent of CD4 memory T cells that expressed CD127 be-
tween the responders and the non-responders at week
24 (data not shown). The percentage of CD127 + CD8 +
CD45RO + T cells had a negative correlation with HBV
viral load (r = −0.47, P = 0.001, Figure 3C).
CD8 memory T cells had elevated expression of CXCR4 in
responders
After defining various subsets of memory T cells
(Figure 4A), we found that a small percent of central
memory T (Tcm) cells in most CHB patients had no sig-
nificant difference in percentage in all patients (data not
shown) between week 0 and week 24, whereas the
CXCR4 expression on CD8 + Tcm cells was up-regulated
at week 24 in the responders (P = 0.039, Figure 4B). Fur-
thermore, the percentage of CXCR4 expressing CD8 +
Tcm and Tem in the responders was higher than that in
the non-responders (P = 0.019, P = 0.04, respectively,
Figure 4C). There was no significant difference in the
CD8 naive and CD4 memory T cell subsets between the
responders and the non-responders.
IFN-γ release increased upon HBV antigen re-challenge
in vitro
After incubating with HBV core antigen (1 ng/ml) for
72 hours in vitro, PBMC from the patients were stimu-
lated with PMA and ionomycin. The expression of IFN-γ
Figure 2 Distributions of different effector molecules expression on memory T cells. (A) Percentages of IFN-γ expression on CD4 memory
T cell between the responders (RE) and the non-responders (NR), which represented the effector molecule of Th1 subsets. (B) Percentages of
IFN-γ expression on CD8 memory T cells between the responders and the non-responders, which represented the effector molecule of cytotoxic
T cells. (C) Percentages of granzyme B and perforin expression on CD8 memory T cells comparison in the responders at week 0 and week 24. (D)
Percentages of granzyme B and perforin expression on CD8 memory T cells between the responders and the non-responders at week 24. (E)
Gating strategy in analysis of granzyme B and perforin expression on CD8 memory T cells by ICCS.
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Figure 3 Percentage of CD127 expression on CD8 memory T
cells. (A) Percentage of CD127 expression on CD8 memory T cells
comparison between week 0 and week 24 in the responders. (B)
Percentage of CD127 expression on CD8 memory T cells
comparison between the responders (RE) and the non-responders
(NR) at 24 week. (C.) Correlation between the percentage of
CD127 + CD8 memory T cells and HBV loads.
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procedure as shown in Figure 5A. Replicated experiments
were performed in each group simultaneously. The per-
centage of IFN-γ expressing CD4 and CD8 memory Tcells were higher in the responder group than those in the
non-responder group (Figure 5B), indicating that memory
Th1 and CTL in the responders predominate in similar
antigen recurrence as well.
Discussion
Effector T cell dysfunction plays a vital role in the major-
ity of chronic HBV infection and the severity of CHB
progression [14,15]. It has been reported that recovery
of T cell function might reverse antiviral effect in host
immunity and hinder the progression of chronic inflam-
mation and fibrosis [16,17]. However, little is known
about the status of memory T cells and the related func-
tional recovery after pegylated IFN- α treatment. During
interferon treatment in chronic HBV infection, CD8+
and CD4+ T cell differentiation following virus clearance
results in the formation of high quality, long-lived mem-
ory cells [18]. Two key features of memory immunocytes
are long-term persistence in the absence of antigen and
rapid response upon re-exposure to the pathogen, which
allow them to transfer to effector cells and confer pro-
tective immunity. This recall response is characterized
by rapid elaboration of effector functions such as cyto-
toxicity, cytokine production, effector T cell proliferation
accompanied by substantial increase in the number of
activated T cells, and effector T cell migration to infec-
tion sites [19,20].
In this study, we found that pegylated IFN- α treat-
ment enhanced CD8 memory T cells recovery by down-
regulating expression of inhibitory receptors on memory
T cells in CHB patients. Our previous study [21] indi-
cated that PD-1 and its ligand—programmed death lig-
and-1(PD-L1), expressed mainly on antigen present cells
(APC)—were down-regulated in intrahepatic and per-
ipheral lymphocytes after pegylated IFN- α treatment.
As HBV antigen or viral load increases, these virus spe-
cific CD8+ T cells may express high levels of PD-1 in re-
sponse to polyfunctional cell loss and effector cell
dysfunction in a hierarchical manner. The pattern of in-
hibitory receptor co-expression and the frequency of
receptors simultaneously expressed by the same CD8
memory T cell can substantially affect the severity of
antiviral effector cell dysfunction [22,23]. CD244 is a
novel biomarker, which has been reported to be mainly
expressed on nature killer cells, involved in partial ex-
haustion of activated T cells [24]. Interestingly, PD-1 and
CD244 co-expression facilitates the increased suscepti-
bility to apoptosis of memory T cells, and reversing the
expression of these receptors implies the recovery of
antiviral immunity. In line with our previous study
regarding CHB patients treated with interferon-α-2b,
which attained down-regulation of inhibitory receptors
accompanied with viremia control [25], we found that
PD-1 and CD244 were down-regulated preferentially in
Figure 4 (See legend on next page.)
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Figure 4 Distribution of CXCR4 expression on CD8 memory T subsets. (A) Gating strategy on defining memory T cell subsets: Naïve cells were
defined as CD45RO-CCR7+ group. Memory cells were defined as CD45RO + CCR7+ group (central memory, Tcm) or CD45RO+ CCR7- group (effector
memory, Tem). (B) Percentage of CXCR4 expression on CD8 Tcm in responders comparison between week 0 and week 24. (C) Percentage of CXCR4
expression on CD8 memory T subsets comparison between responders (black dots) and non-responders(black triangle) at week 24.
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Dynamic down-regulation of inhibitory receptor expres-
sion on CD8 memory T cells indicates functional T cell
recovery. However, these results were not observed on
CD4 memory T cells, which may be due to limited sam-
ples and need further investigation.
Chemokines and their receptors are essential in mem-
ory T cell migration and homing and directing mature
activated T cells to lymphoid tissues and other immune
microenvironments that are suitable for their differenti-
ation and function. The chemokine receptor CXCR4
belongs to the superfamily of G-protein-coupled recep-
tors [26,27]. A recent report has highlighted the role of
CXCR4 as a prognostic marker in various types of can-
cer, including leukemia and breast cancer [28]. CXCR4
and CCR5 are also co-receptors for HIV entry into
human cells [29], but their roles in viral hepatitis have
not yet been addressed. Formation of highly functional
memory T cells accompany viral control during antiviral
treatment. Once they encounter the viral antigens again,
the populations of memory CD4 + and CD8+ T cells ex-
pand in lymphoid tissue and then immigrate to the per-
iphery where they bind with their ligands and are then
activated to take effect. The chemokine receptors that
are highly expressed on memory T cells not only prepare
them for life in the periphery but are also correlated
with the outcome of antiviral treatment. CCR7+ T
cmcells are capable of proliferating and transferring to
CCR7- Tem cells after activation, while cytokine produc-
tion are enriched in Tem cells [30]. Interestingly, we
found that CXCR4 was highly expressed on a subset of
CD8 memory T cells in the responders, suggesting that
memory T activation is accompanied with dramatic
alterations in chemokine responsiveness. In our investi-
gation, we found that CXCR4 was more highly expressed
on CD8+ Tcm cells of the responders than on those of
the non-responders, indicating that migration of Tcm
(CD45RO + CCR7+) reverted after pegylated IFN-α
treatment. Therefore, we postulate that higher co-
expression of CCR7 and CXCR4 on memory T cells
represents the potent mobility that can affect targets in
antiviral treatment. These memory T cells with high che-
mokine receptor expression may serve to ensure a
robust cycle of antigen-specific memory T-cell activation
and proliferation. Unfortunately, CXCR4 and CCR7 tend
to shed in culture in response to antigen stimulation,
and it is hard to measure the effector cytokines
expressed on memory T subset in this scenario.CD127 is the α chain of the interleukin-7 (IL-7) recep-
tor, and it’s mainly expressed on T cells. IL-7 is a survival
cytokine of memory T cells and forms a feedback loop
with its receptor expression in the immune milieu.
Chronic viral infection induces a significant decrease in
CD127 expression on CD8+ T cells [31,32]. Studies elu-
cidated that high CD127 expression indicates the
enhanced function of memory T cells in viral clearance.
Reported data strongly support that the rejuvenated
cellular responses correlate with the homeostasis and
proliferation of functional T cells, but the underlying
mechanisms remain unclear [33-35]. In this study, we
found that CD127 expression on CD8 memory T cells
was significantly higher in the responders than in the
non-responders, which indicated that proliferation took
place predominately in the responders after pegylated
IFN-α treatment and reinvigorated the T cells activation.
However, the detailed mechanisms and immunological
changes need further investigation. Meanwhile, CD127
expression was tightly correlated with HBV DNA load,
suggesting that up-regulated CD127 expression in pegy-
lated IFN-α treatment may be a novel biomarker to pre-
dict the outcome of antiviral treatment.
T cell dysfunction becomes progressively worse as viral
load increases or inhibitory signals are upregulated.
Bertoletti et al. indicated that interferon release lagged
behind innate immune response in certain HBV infec-
tions. CD8 +memory T cells in the adaptive immune
system take action upon encountering replicating HBV
virus [36,37]. Tcm proliferation and differentiation into
effector T cells contribute to pathogen elimination by
perforin-dependent cytolysis and secretion of other func-
tional cytokines [38]. In this study, the expression of
effector molecules such as perforin and granzyme B on
memory T cells were up-regulated, which enhanced the
host antiviral activity by using exogenous interferon. But
the perforin and granzyme B expressions on memory
CD8+ T cells in responders were not higher than those
in the non-responders at week 24. We speculate that the
effector molecules synthetized in CD8 memory T cells
mainly induce apoptosis and necrosis of virally infected
cells, whereas memory T cells in the responders acquired
viral control via the feedback of lower granzyme B and
perforin expressions. IFN-γ expression on both CD4 and
CD8 memory T cells was up-regulated after pegylated
IFN-α treatment, indicating the potent generation of
type 1 T helper cells and cytotoxic activity in the respon-
ders. These classical cell types are in charge of antiviral
Figure 5 Percentage of IFN-γ expression on memory T cells after isolated PBMC incubated with exogenous HBV core antigen in vitro.
(A) Gating strategy in analysis of IFN-γ expression on CD4 and CD8 memory T cells after the stimulation. (B) An example of IFN-γ expression on
CD4 and CD8 memory T cells each from the responders and the non-responders under the same stimulating condition.
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Table 2 Combinations of staining antibody panels
FITC PE PerCP APC
Panel 1 CD3 CD45RO CD4 PD-1
Panel 2 CD3 CD45RO CD8 PD-1
Panel 3 CD244 CD45RO CD4 CD3
Panel 4 CD244 CD45RO CD8 CD3
Panel 5 Granzyme B CD45RO CD8 CD3
Panel 6 CD3 Perforin CD8 CD45RO
Panel 7 CD3 IFN CD4 CD45RO
Panel 8 CD3 IFN CD8 CD45RO
Panel 9 CD3 None 7-AAD CD45RO
Each row represents a combination of four staining antibodies in each panel;
each column represents the different antibodies in each flow cytometry
channel.
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was up-regulated dramatically after in vitro HBV core
antigen re-challenging, reflecting the sensitive and po-
tent capability of memory in the responders, which may
predict long-term viral control after the treatment.
Taken together, we found that memory T cells
recovered after pegylated IFN- α treatment via down-
regulation of inhibitory receptors, up-regulation of che-
mokine and survival cytokine receptors, and enhanced
production of effector molecules. Therefore, pegylated
IFN- α regulates memory T cell functions during persist-
ent chronic HBV infection. A better understanding of
the characteristics and mechanisms responsible for
memory T cell dysfunction and recovery during antiviral
therapy helps one to develop sensitive immunological
markers for predicting the outcome of antiviral treat-
ment and vaccine approaches that reduce the disease
burden of intractable chronic infections. These results
were obtained from a small scale follow-up of CHB
patients treated with pegylated IFN-α. A further study is
needed with increased sample size and a longer period
of follow-up.
Conclusion
Pegylated IFN-α treatment enhanced recovery of mem-
ory T cells in CHB patients via down-regulating inhibi-
tory receptors PD-1 and CD244 and up-regulating
effector molecules perforin, granzyme B and IFN-γ. The
responders had a rapid and potent recall response upon
reencountering viral antigen in vitro. The expression of
CXCR4 and CD127 on CD8 memory T cell may be used
to predict outcome of the treatment.
Materials and methods
Patients and study design
The consecutive CHB patients enrolled in the Peking
University First Hospital Research Center for Liver Dis-
eases and Infectious Diseases Department were followed
between February 2011 and November 2011. The proto-
cols involved in this study were approved and monitored
by the Peking University First Hospital Research Ethics
Board, and all patients signed informed consent forms in
accordance with the Declaration of Helsinki. Diagnosis
of chronic HBV infection was established as previously
described [39]. Samples collected from e antigen positive
chronic HBV individuals were naïve to nucleotide ana-
logs (NAs) or interferon. All subjects were antibody
negative to hepatitis A, C, and D viruses, and did not
have other liver diseases, including alcohol abuse and
autoimmune hepatitis. No subjects had decompensated
liver disease (evidence or history of ascites, variceal
bleeding, or hepatic encephalopathy). The patients were
treated with pegylated IFN-α viasubcutaneous injection
once a week for 24 weeks. Clinical and laboratory datafrom the patients were collected at week 0 (before treat-
ment) and at week 24 (after treatment).
Laboratory assays
Plasma HBV DNA monitoring and Serological assessment
Plasma HBV DNA was quantified by TaqMan real-time
polymerase chain reaction assay (Roche,USA). The detec-
tion sensitivity was 60 copies/mL. HBV DNA (IU/mL)
was logarithmically transformed for analysis purposes.
Serum levels of liver enzyme alanine aminotransferase
(ALT) were measured with a Hitachi-7180 automatic
biochemistry analyzer (Hi-tachi Inc., Japan) following
standard laboratory methods.
Regeants
Staining antibodies CD127-FITC, CD244-FITC, CD3-F
ITC,CXCR4-PE, PD-1-APC, CD8-PerCP, 7-AAD-PerCP,
CD3-APC, and CD4-PerCP were purchased from BD
Biosciences (San Jose, CA, USA), CCR7-FITC from
eBioscience (San Diego, CA, USA), IFN-γ-FITC,
CD45RO-PE from R&D Systems (Minneapolis, MN,
USA), CD45RO-APC from BD pharmingen (San Jose,
CA, USA), and Granzyme B-FITC and Perforin -PE from
BioLegend (San Diego, CA, USA).
Blood cell staining
Freshly heparinized blood samples collected from CHB
patients were aliquoted into different tubes. Each tube
was incubated with the antibodies combination as the
study designed and corresponding antibody isotypes.
The samples were then processed by a red blood cell lys-
ing solution (BD, CA, USA) and washed twice with
phosphate buffered saline (PBS, Gibco, USA)), and fixed
with 1% paraformaldehyde. As for ICCS, lysed blood
samples were first stained with surface antibodies com-
bination, and then were washed, fixed and permeabilized
(Fix/Perm, eBioscience) according to the manufacturer
instructions.
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cells from patients were cultured in 800μL RPMI-1640
medium containing 10% fetal calf serum (FCS), PMA
(300 ng/ml; Sigma-Aldrich, St. Louis, MO, USA), iono-
mycin (100 ng/ml Invitrogen, Ontario, Canada), and
Golgi Stop (1 μl/ml, BD San Jose, CA, USA) at 37°C, 5%
CO2 for 5 hours. ICCS was repeated. Cell viability was
assessed by 7-aminoactinomycin D (7-AAD) staining
(BD Biosciences, San Jose, CA, USA).
PBMC isolation and cell stimulation in vitro
Freshly heparinized blood samples from CHB patients
were two-fold diluted with RPMI-1640 medium contain-
ing 10% heat-inactivated FCS. PBMC were isolated by
Ficoll-PaqueTM PLUS (GE Healthcare Bio-sciences,
Sweden) and resuspended in RPMI-1640 medium sup-
plemented with 300 μg/mL L-glutamin, 100 U/mL peni-
cillin, 100 μg/mL streptomycin, and 10% FCS. The
isolated PBMC were then cultured with recombinated
HBV core antigen (1 ng/ml, 1–183 amino acid, Cali-Bio,
USA) and recombinant human IL-2 (50 IU/ml, Pepro-
tech, UK) in 24-well plates (Corning, USA) at the dens-
ity of 5 × 105/mLfor 72 hours before they were
stimulated withPMA and ionomycin following the pro-
cedure described in IFN-γ stimulation assay. The release
of intracellular cytokines from Golgi body was blocked
by using Golgi Plug (1 μl/ml, BD San Jose, CA, USA) in
this assay.
Flow cytometry
Flow cytometric analysis was performed on the FACS
Calibur 4-color flow cytometer (Becton Dickinson,
USA), and immunophenotypic sorting was analyzed
using Flow Jo, version 7.5 (Tree star, OR, USA). Staining
panels and antibody combinations are shown in the
Table 2.
Statistical analysis
All data were analyzed using GraphPad Prism 5.0
software (San Diego, CA, USA). Statistical differences
between groups were determined by using the nonpara-
metric Mann–Whitney U test. Data from the same indi-
viduals were compared by using the Wilcoxon matched
pairs test. Correlations between variables were evaluated
using Spearman method. For all tests, a P-value of less
than 0.05 was considered to be a significant difference.
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